Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study

Wanda K. O'Neal, Wayne Anderson, Patricia V. Basta, Elizabeth E. Carretta, Claire M. Doerschuk, R. G. Barr, Eugene R. Bleecker, Stephanie A. Christenson, Jeffrey L. Curtis, Meilan K. Han, Nadia N. Hansel, Richard E. Kanner, Eric C. Kleerup, Fernando J. Martinez, Bruce E. Miller, Stephen P. Peters, Stephen I. Rennard, Mary B. Scholand, Ruth Tal-Singer, Prescott G. WoodruffDavid J. Couper, Sonia M. Davis

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: As a part of the longitudinal Chronic Obstructive Pulmonary Disease (COPD) study, Subpopulations and Intermediate Outcome Measures in COPD study (SPIROMICS), blood samples are being collected from 3200 subjects with the goal of identifying blood biomarkers for sub-phenotyping patients and predicting disease progression. To determine the most reliable sample type for measuring specific blood analytes in the cohort, a pilot study was performed from a subset of 24 subjects comparing serum, Ethylenediaminetetraacetic acid (EDTA) plasma, and EDTA plasma with proteinase inhibitors (P100™).Methods: 105 analytes, chosen for potential relevance to COPD, arranged in 12 multiplex and one simplex platform (Myriad-RBM) were evaluated in duplicate from the three sample types from 24 subjects. The reliability coefficient and the coefficient of variation (CV) were calculated. The performance of each analyte and mean analyte levels were evaluated across sample types.Results: 20% of analytes were not consistently detectable in any sample type. Higher reliability and/or smaller CV were determined for 12 analytes in EDTA plasma compared to serum, and for 11 analytes in serum compared to EDTA plasma. While reliability measures were similar for EDTA plasma and P100 plasma for a majority of analytes, CV was modestly increased in P100 plasma for eight analytes. Each analyte within a multiplex produced independent measurement characteristics, complicating selection of sample type for individual multiplexes.Conclusions: There were notable detectability and measurability differences between serum and plasma. Multiplexing may not be ideal if large reliability differences exist across analytes measured within the multiplex, especially if values differ based on sample type. For some analytes, the large CV should be considered during experimental design, and the use of duplicate and/or triplicate samples may be necessary. These results should prove useful for studies evaluating selection of samples for evaluation of potential blood biomarkers.

Original languageEnglish (US)
Article number9
JournalJournal of Translational Medicine
Volume12
Issue number1
DOIs
StatePublished - Jan 8 2014

Fingerprint

Pulmonary diseases
Biomarkers
Edetic Acid
Chronic Obstructive Pulmonary Disease
Assays
Outcome Assessment (Health Care)
Plasmas
Serum
Blood
Multiplexing
Design of experiments
Disease Progression
Peptide Hydrolases
Research Design

Keywords

  • Biomarkers
  • Blood analytes
  • COPD
  • Chronic obstructive pulmonary disease
  • EDTA plasma
  • Multiplex assays
  • P100 plasma
  • Pilot study
  • SPIROMICS
  • Serum

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. / O'Neal, Wanda K.; Anderson, Wayne; Basta, Patricia V.; Carretta, Elizabeth E.; Doerschuk, Claire M.; Barr, R. G.; Bleecker, Eugene R.; Christenson, Stephanie A.; Curtis, Jeffrey L.; Han, Meilan K.; Hansel, Nadia N.; Kanner, Richard E.; Kleerup, Eric C.; Martinez, Fernando J.; Miller, Bruce E.; Peters, Stephen P.; Rennard, Stephen I.; Scholand, Mary B.; Tal-Singer, Ruth; Woodruff, Prescott G.; Couper, David J.; Davis, Sonia M.

In: Journal of Translational Medicine, Vol. 12, No. 1, 9, 08.01.2014.

Research output: Contribution to journalArticle

O'Neal, WK, Anderson, W, Basta, PV, Carretta, EE, Doerschuk, CM, Barr, RG, Bleecker, ER, Christenson, SA, Curtis, JL, Han, MK, Hansel, NN, Kanner, RE, Kleerup, EC, Martinez, FJ, Miller, BE, Peters, SP, Rennard, SI, Scholand, MB, Tal-Singer, R, Woodruff, PG, Couper, DJ & Davis, SM 2014, 'Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study', Journal of Translational Medicine, vol. 12, no. 1, 9. https://doi.org/10.1186/1479-5876-12-9
O'Neal, Wanda K. ; Anderson, Wayne ; Basta, Patricia V. ; Carretta, Elizabeth E. ; Doerschuk, Claire M. ; Barr, R. G. ; Bleecker, Eugene R. ; Christenson, Stephanie A. ; Curtis, Jeffrey L. ; Han, Meilan K. ; Hansel, Nadia N. ; Kanner, Richard E. ; Kleerup, Eric C. ; Martinez, Fernando J. ; Miller, Bruce E. ; Peters, Stephen P. ; Rennard, Stephen I. ; Scholand, Mary B. ; Tal-Singer, Ruth ; Woodruff, Prescott G. ; Couper, David J. ; Davis, Sonia M. / Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. In: Journal of Translational Medicine. 2014 ; Vol. 12, No. 1.
@article{ed74e19007dc46038c20ffd2d7a861b6,
title = "Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study",
abstract = "Background: As a part of the longitudinal Chronic Obstructive Pulmonary Disease (COPD) study, Subpopulations and Intermediate Outcome Measures in COPD study (SPIROMICS), blood samples are being collected from 3200 subjects with the goal of identifying blood biomarkers for sub-phenotyping patients and predicting disease progression. To determine the most reliable sample type for measuring specific blood analytes in the cohort, a pilot study was performed from a subset of 24 subjects comparing serum, Ethylenediaminetetraacetic acid (EDTA) plasma, and EDTA plasma with proteinase inhibitors (P100™).Methods: 105 analytes, chosen for potential relevance to COPD, arranged in 12 multiplex and one simplex platform (Myriad-RBM) were evaluated in duplicate from the three sample types from 24 subjects. The reliability coefficient and the coefficient of variation (CV) were calculated. The performance of each analyte and mean analyte levels were evaluated across sample types.Results: 20{\%} of analytes were not consistently detectable in any sample type. Higher reliability and/or smaller CV were determined for 12 analytes in EDTA plasma compared to serum, and for 11 analytes in serum compared to EDTA plasma. While reliability measures were similar for EDTA plasma and P100 plasma for a majority of analytes, CV was modestly increased in P100 plasma for eight analytes. Each analyte within a multiplex produced independent measurement characteristics, complicating selection of sample type for individual multiplexes.Conclusions: There were notable detectability and measurability differences between serum and plasma. Multiplexing may not be ideal if large reliability differences exist across analytes measured within the multiplex, especially if values differ based on sample type. For some analytes, the large CV should be considered during experimental design, and the use of duplicate and/or triplicate samples may be necessary. These results should prove useful for studies evaluating selection of samples for evaluation of potential blood biomarkers.",
keywords = "Biomarkers, Blood analytes, COPD, Chronic obstructive pulmonary disease, EDTA plasma, Multiplex assays, P100 plasma, Pilot study, SPIROMICS, Serum",
author = "O'Neal, {Wanda K.} and Wayne Anderson and Basta, {Patricia V.} and Carretta, {Elizabeth E.} and Doerschuk, {Claire M.} and Barr, {R. G.} and Bleecker, {Eugene R.} and Christenson, {Stephanie A.} and Curtis, {Jeffrey L.} and Han, {Meilan K.} and Hansel, {Nadia N.} and Kanner, {Richard E.} and Kleerup, {Eric C.} and Martinez, {Fernando J.} and Miller, {Bruce E.} and Peters, {Stephen P.} and Rennard, {Stephen I.} and Scholand, {Mary B.} and Ruth Tal-Singer and Woodruff, {Prescott G.} and Couper, {David J.} and Davis, {Sonia M.}",
year = "2014",
month = "1",
day = "8",
doi = "10.1186/1479-5876-12-9",
language = "English (US)",
volume = "12",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study

AU - O'Neal, Wanda K.

AU - Anderson, Wayne

AU - Basta, Patricia V.

AU - Carretta, Elizabeth E.

AU - Doerschuk, Claire M.

AU - Barr, R. G.

AU - Bleecker, Eugene R.

AU - Christenson, Stephanie A.

AU - Curtis, Jeffrey L.

AU - Han, Meilan K.

AU - Hansel, Nadia N.

AU - Kanner, Richard E.

AU - Kleerup, Eric C.

AU - Martinez, Fernando J.

AU - Miller, Bruce E.

AU - Peters, Stephen P.

AU - Rennard, Stephen I.

AU - Scholand, Mary B.

AU - Tal-Singer, Ruth

AU - Woodruff, Prescott G.

AU - Couper, David J.

AU - Davis, Sonia M.

PY - 2014/1/8

Y1 - 2014/1/8

N2 - Background: As a part of the longitudinal Chronic Obstructive Pulmonary Disease (COPD) study, Subpopulations and Intermediate Outcome Measures in COPD study (SPIROMICS), blood samples are being collected from 3200 subjects with the goal of identifying blood biomarkers for sub-phenotyping patients and predicting disease progression. To determine the most reliable sample type for measuring specific blood analytes in the cohort, a pilot study was performed from a subset of 24 subjects comparing serum, Ethylenediaminetetraacetic acid (EDTA) plasma, and EDTA plasma with proteinase inhibitors (P100™).Methods: 105 analytes, chosen for potential relevance to COPD, arranged in 12 multiplex and one simplex platform (Myriad-RBM) were evaluated in duplicate from the three sample types from 24 subjects. The reliability coefficient and the coefficient of variation (CV) were calculated. The performance of each analyte and mean analyte levels were evaluated across sample types.Results: 20% of analytes were not consistently detectable in any sample type. Higher reliability and/or smaller CV were determined for 12 analytes in EDTA plasma compared to serum, and for 11 analytes in serum compared to EDTA plasma. While reliability measures were similar for EDTA plasma and P100 plasma for a majority of analytes, CV was modestly increased in P100 plasma for eight analytes. Each analyte within a multiplex produced independent measurement characteristics, complicating selection of sample type for individual multiplexes.Conclusions: There were notable detectability and measurability differences between serum and plasma. Multiplexing may not be ideal if large reliability differences exist across analytes measured within the multiplex, especially if values differ based on sample type. For some analytes, the large CV should be considered during experimental design, and the use of duplicate and/or triplicate samples may be necessary. These results should prove useful for studies evaluating selection of samples for evaluation of potential blood biomarkers.

AB - Background: As a part of the longitudinal Chronic Obstructive Pulmonary Disease (COPD) study, Subpopulations and Intermediate Outcome Measures in COPD study (SPIROMICS), blood samples are being collected from 3200 subjects with the goal of identifying blood biomarkers for sub-phenotyping patients and predicting disease progression. To determine the most reliable sample type for measuring specific blood analytes in the cohort, a pilot study was performed from a subset of 24 subjects comparing serum, Ethylenediaminetetraacetic acid (EDTA) plasma, and EDTA plasma with proteinase inhibitors (P100™).Methods: 105 analytes, chosen for potential relevance to COPD, arranged in 12 multiplex and one simplex platform (Myriad-RBM) were evaluated in duplicate from the three sample types from 24 subjects. The reliability coefficient and the coefficient of variation (CV) were calculated. The performance of each analyte and mean analyte levels were evaluated across sample types.Results: 20% of analytes were not consistently detectable in any sample type. Higher reliability and/or smaller CV were determined for 12 analytes in EDTA plasma compared to serum, and for 11 analytes in serum compared to EDTA plasma. While reliability measures were similar for EDTA plasma and P100 plasma for a majority of analytes, CV was modestly increased in P100 plasma for eight analytes. Each analyte within a multiplex produced independent measurement characteristics, complicating selection of sample type for individual multiplexes.Conclusions: There were notable detectability and measurability differences between serum and plasma. Multiplexing may not be ideal if large reliability differences exist across analytes measured within the multiplex, especially if values differ based on sample type. For some analytes, the large CV should be considered during experimental design, and the use of duplicate and/or triplicate samples may be necessary. These results should prove useful for studies evaluating selection of samples for evaluation of potential blood biomarkers.

KW - Biomarkers

KW - Blood analytes

KW - COPD

KW - Chronic obstructive pulmonary disease

KW - EDTA plasma

KW - Multiplex assays

KW - P100 plasma

KW - Pilot study

KW - SPIROMICS

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=84892173588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892173588&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-12-9

DO - 10.1186/1479-5876-12-9

M3 - Article

C2 - 24397870

AN - SCOPUS:84892173588

VL - 12

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 9

ER -